Our Communities
Patients
Your story is unique. We’re here to support you every step of the health journey so that you can live longer healthier and with greater peace of mind.
Our Tests
Screening and health risk assessment
LucenceINSIGHT is a multi-cancer early detection (MCED) next-generation sequencing (NGS) blood test that screens for up to 50 cancers with 99% specificity (low false-positives).
The test uses Lucence's mirror barcoding technology to detect ctDNA, ctRNA, and viral DNA. It can then predict tumor location with machine learning.
This is a prescription only screening test.
LucenceINSIGHT does not diagnose cancer. Further confirmatory testing is recommended for positive results.
Available internationally outside the USA.
CardioHemeRISK is a next-generation sequencing (NGS) blood test. The test detects clonal hematopoiesis (CH) mutations to assess the risk of developing heart attack, stroke and leukemia.
This is a prescription only screening test.
CardioHemeRISK does not diagnose heart attack, stroke, or leukemia. Further confirmatory testing is recommended for positive results.
Available internationally outside the USA.
LucenceLONGEVITY is a combination of our LucenceINSIGHT 50 and CardioHemeRISK tests.
LucenceINSIGHT 50 is a multi-cancer early detection (MCED) next-generation sequencing (NGS) blood test that screens for 50 cancers with 99% specificity (low false-positives)
CardioHemeRISK is a next-generation sequencing (NGS) blood test. The test detects clonal hematopoiesis (CH) mutations to assess the risk of developing heart attack, stroke and leukemia.
LucenceINSIGHT and CardioHemeRISK are prescription only screening tests.
LucenceINSIGHT does not diagnose cancer. CardioHemeRISK does not diagnose heart attack, stroke, or leukemia. Further confirmatory testing is recommended for positive results.
Available internationally outside the USA.
Treatment selection
LiquidHALLMARK is an ultrasensitive blood test designed to detect tumor-derived ctDNA and ctRNA to identify cancer-related mutations and biomarkers with a single blood draw.
LiquidMARK is a focused sub-panel for targeted cancer types. It uses the same test process as LiquidHALLMARK to detect tumor-derived ctDNA to identify cancer-related mutations and biomarkers with a single blood draw.
LiquidHALLMARK and LiquidMARK are prescription only tests.
LiquidHALLMARK is available internationally including the USA.
LiquidMARK is available internationally outside the USA.
UNITED 600 is a comprehensive genomic profiling tissue-based test. It detects cancer-related DNA and RNA mutations and calculates total number of mutations (tumor mutational burden) from FFPE tissue samples to inform personalized therapy selection.
This is a prescription only test.
Available internationally outside the USA.
UNITED CNS is a next-generation sequencing (NGS) tissue test panel for classifying central nervous system (CNS) cancers. It meets WHO CNS5 standard-of-care in aiding in the classification of CNS cancer subtypes and grades to support accurate diagnosis and treatment.
This is a prescription only test.
Available internationally outside the USA.
Hereditary risk assessment
Our Lumi Series tests examine genes that are associated with hereditary cancers for risk assessment, cancer screening and matching with targeted therapy at 99% sensitivity.
Tests in our Lumi Series:-
LumiRISK™
-
LumiTHERA™
-
LumiFOCUS™
LumiRISK, LumiTHERA, and LumiFOCUS are prescription only tests.
Available internationally outside the USA.-
Treatment response monitoring
LucenceMONITOR is a minimal residual disease (MRD) test that screens for the recurrence of 6 cancers: breast, colorectal, lung, liver, pancreatic, and biliary tract cancer.
The test uses detects circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) from cancer cells to track tumor-specific mutations.
This is a prescription only test.
Available internationally outside the USA.
Talk to your doctor about whether testing is right for you.
Frequently Asked Questions
Cancer is a disease caused by genetic changes within cells of our body. Harmful mutations can cause normal cells to grow and divide uncontrollably, leading to cancer. Genetic testing or tumor profiling can identify unique combinations of mutations within a patient’s tumor.
Circulating tumor DNA (ctDNA) is genetic material that is shed by dying cancer cells. Circulating tumor RNA (ctRNA) is genetic material that is actively released by living cancer cells. Both ctDNA and ctRNA are cancer signals that can be detected in the blood for genetic testing to help your doctor select the appropriate treatment for your cancer.
Clonal hematopoiesis (CH) is common disorder acquired as an age- and lifestyle-related inflammatory process. It starts typically above age 40 when one blood stem cell develops a mutation and begins making lots of blood cells (clonal expansion) with the same mutation. It is not cancer. Individuals with clonal hematopoiesis have a higher risk of developing cardiovascular and hematological diseases like heart attack, stroke and leukemia.Your doctor will order the appropriate test for you. For tissue biopsy tests, a tissue sample will be obtained from your cancer. Typically your blood is drawn for liquid biopsy tests, but the sample may vary at the doctor's discretion. All samples are sent to to our laboratory in Singapore for testing. Your report will be sent to your doctor directly and they will discuss the results with you.
We have solutions for every step for the healthcare journey, from hereditary risk assessment, to screening and health risk assessment, to treatment response monitoring to treatment selection. Talk to your doctor about whether testing is right for you.
View our list of solutions here.